Literature DB >> 18837898

Surgical treatment of pancreatic cancer.

Martin Loos1, Jörg Kleeff, Helmut Friess, Markus W Büchler.   

Abstract

Pancreatic cancer is an aggressive disease with an overall 5-year survival rate of less than 5%. Up to date, surgical resection represents the basis of treatment for localized pancreatic cancer and remains the only chance for cure. Due to continuous improvements in surgical techniques and perioperative care, pancreatic resections have evolved into safe surgical procedures with low mortality and acceptable morbidity rates for experienced surgeons in high-volume centers. Recently, more aggressive approaches including extended lymphadenectomy, vascular resection, surgery for metastastic or recurrent disease, and multimodal regimens have been suggested to improve long-term outcome. This article provides an overview on current standard procedures and summarizes new strategies in the surgical treatment of pancreatic cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18837898     DOI: 10.1196/annals.1414.024

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  34 in total

Review 1.  Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Authors:  Jie-Er Ying; Li-Ming Zhu; Bi-Xia Liu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.

Authors:  Wei Li; Jiguang Ma; Qingyong Ma; Bin Li; Liang Han; Jiangbo Liu; Qinhong Xu; Wanxing Duan; Shuo Yu; Fengfei Wang; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response.

Authors:  Dickson K Kirui; Christian Celia; Roberto Molinaro; Shyam S Bansal; Donato Cosco; Massimo Fresta; Haifa Shen; Mauro Ferrari
Journal:  Adv Healthc Mater       Date:  2015-02-26       Impact factor: 9.933

4.  Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation.

Authors:  Jian Du; Jingwen Wang; Guang Tan; Zhengang Cai; Lu Zhang; Bo Tang; Zhongyu Wang
Journal:  Med Oncol       Date:  2012-02-07       Impact factor: 3.064

5.  Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer.

Authors:  Can A Karaca; Ahmet Coker
Journal:  Indian J Surg Oncol       Date:  2018-10-26

6.  The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells.

Authors:  Xiaodong Tang; Shuanghai Liu; Dawei Chen; Zhenguo Zhao; Jiahua Zhou
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

7.  A comprehensive analysis of candidate genes and pathways in pancreatic cancer.

Authors:  Jie Liu; Jun Li; Hali Li; Aidong Li; Biou Liu; Liou Han
Journal:  Tumour Biol       Date:  2014-11-20

8.  Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation.

Authors:  Jinluan Li; Jianji Pan; Xianggao Zhu; Ying Su; Lingling Bao; Sufang Qiu; Changyan Zou; Yong Cai; Junxin Wu; Ivan W K Tham
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

9.  Incidence and prognostic impact of para-aortic lymph nodes metastases during pancreaticoduodenectomy for peri-ampullary cancer.

Authors:  Gennaro Nappo; Domenico Borzomati; Giuseppe Perrone; Sergio Valeri; Michela Amato; Tommasangelo Petitti; Roberto Coppola
Journal:  HPB (Oxford)       Date:  2015-09-03       Impact factor: 3.647

10.  Gli1 maintains cell survival by up-regulating IGFBP6 and Bcl-2 through promoter regions in parallel manner in pancreatic cancer cells.

Authors:  Xuan-Fu Xu; Chuan-Yong Guo; Jun Liu; Wen-Juan Yang; Yu-Jing Xia; Ling Xu; Yong-Chun Yu; Xing-Peng Wang
Journal:  J Carcinog       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.